Business Wire

PUMA

13.3.2024 12:27:35 CET | Business Wire | Press release

Share
PUMA Reduces Greenhouse Gas Emissions by 24% in 2023

Sports company PUMA reduced its greenhouse gas emissions by 24% in 2023 compared to 2022, despite a strong sales growth.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240313721861/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Sports company PUMA reduced its greenhouse gas emissions by 24% in 2023 compared to 2022, despite a strong sales growth. (Photo: Business Wire)

This was made possible by its core suppliers doubling their use of renewable energy in 2023 compared to the previous year, increasing the use of less carbon intensive materials in its products, the introduction of low carbon shipment tariffs by PUMA’s logistics partner Maersk, by using renewable electricity or purchasing renewable energy certificates at its own operations and by investing in electric vehicles in its car fleet. Compared with the 2017 baseline, this means an absolute greenhouse gas emission reduction of 29%.

“We are very proud of the progress we have achieved on our sustainability journey in 2023, particularly when it comes to the reduction of greenhouse gases,” said Anne-Laure Descours, Chief Sourcing Officer at PUMA. “We will not stop there, however, and continue to execute our FOREVER.BETTER. sustainability strategy and our 10FOR25 targets.”

With an 85% reduction of own emissions and a 65% reduction of supply chain emissions relative to sales, PUMA achieved its first science-based greenhouse gas reduction target in 2023, seven years ahead of the target year 2030. PUMA’s new climate goals, which were approved by the Science Based Targets Initiative (SBTi), aim to reduce PUMA’s emissions by what scientists say is necessary to keep global warming below 1.5 degrees. By 2030, PUMA aims to reduce its absolute Scope 1 and 2 GHG emissions by 90% from a 2017 baseline year. The SBTi has classified PUMA Scope 1 and 2 targets as in line with a 1.5-degree trajectory. By 2030, PUMA also commits to reduce absolute Scope 3 GHG emissions from its supply chain and logistics by 33% compared to 2017.

Apart from increasing its climate ambitions, PUMA also made progress with its other 10FOR25 sustainability targets, reaching two out of ten targets ahead of schedule.

PUMA met its Plastics and the Oceans target by eliminating plastic carrier bags from its owned and operated stores and through researching biodegradable plastic options. An important part of this target was PUMA’s successful RE:SUEDE experiment, where it turned an experimental version of its classic Suede sneaker into compost under controlled industrial conditions. A commercial version will be launched in April 2024.

It also achieved its Human Rights target by training more than 220,000 factory workers on women’s empowerment and completely mapping subcontractors and Tier 2 suppliers for human rights risks. In addition, PUMA employees donated over 57,000 of community engagement hours.

Other progress included scaling up the use of recycled materials in 2023, producing 8 out of 10 products with a significant part of recycled or certified materials. Starting 2024, all* of PUMA’s replica football jerseys will be made using PUMA’s RE:FIBRE recycling technology which focuses on polyester textile waste as the primary source of material.

PUMA’s sustainability report is available at https://about.puma.com/en/sustainability/reporting

*excluding any locally sourced kits and replicas for Al Hilal, Galatasaray SK, Fenerbahce, Shakhtar Donetsk

PUMA

PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For more than 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stitched. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240313721861/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye